Theratechnologies to Host Key Opinion Leader Event to Discuss its SORT1+ Technology™ for the Treatment of All Sortilin-Expr...
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ:
THTX), a biopharmaceutical company focused on the development and
commercialization of innovative therapies, today announced that it
will host a key opinion leader (KOL) webinar on the Company’s
SORT1+ Technology™ and TH1902, its lead investigational
peptide-drug conjugate (PDC) for treating sortilin-expressing
advanced solid tumors, on Monday, June 21, 2021 at 11:00 a.m.
To register for the webinar, please go to:
The webinar will feature a presentation by KOL
Richard Béliveau, Ph.D., Université du Québec à Montréal, who will
discuss the science of receptor-mediated cancer therapy and the
discovery of sortilin as a novel target in cancer treatment. Dr.
Béliveau will be available to answer questions following the formal
presentations. Theratechnologies' President and Chief Executive
Officer Paul Lévesque and Senior Vice President and Chief Medical
Officer Christian Marsolais, Ph.D. will also give an update on its
SORT1+ Technology™ is a new class of cancer
treatment targeting all sortilin-expressing cancers by linking
approved anticancer drugs to a proprietary peptide that
specifically binds to the sortilin receptor. The PDC is
internalized by the sortilin receptor and the therapeutic agent is
released directly inside the cancer cell.
TH1902 was granted fast track designation by the
U.S. Food and Drug Administration (FDA) as a single agent for the
treatment of all advanced solid tumors expressing sortilin that are
refractory to standard therapy and is currently being evaluated in
a Phase 1 clinical trial.
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical
company focused on the development and commercialization of
innovative therapies addressing unmet medical needs. Further
information about Theratechnologies is available on the Company's
website at www.theratech.com, on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov.
For media inquiries:Denis BoucherVice-President, Communications
and Corporate Affairs514-336-7800
For investor inquiries:Leah GibsonSenior Director, Investor
Historical Stock Chart
From Sep 2021 to Oct 2021
Historical Stock Chart
From Oct 2020 to Oct 2021